Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Pamiparib in Advanced Solid Tumors
NCT05038839Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib and pamiparib in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events at 6 months, Dose-limiting toxicities at 28 days and 1 more. Started Feb 2022; status: completed.
02
Drugs
cabozantinibpamiparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05038839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038839.